Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
Deals
Features
News
Region
Sectors
Size
Uncategorised

Series B

Arrakis arranges $75m series B
Osage University has returned for a $75m series B round raised by Arrakis Therapeutics, which has licensed technology from University of Pennsylvania.
Cytora assesses $32.6m series B
Cambridge Innovation Capital and Parkwalk Advisors have both returned to back a $32.6m series B round for Cytora, an insurance technology spinout of Cambridge.
Cardinal Analytx processes series B
Stanford spinout Cardinal Analytx has raised $20.6m out of a targeted $29.3m, adding to a $6.1m series A round backed by Stanford-StartX Fund in 2017.
Aqdot emulsifies $7.8m series B
Cambridge-founded chemicals products maker Aqdot has welcomed the return of IP Group and Parkwalk Advisors in its latest round, taking its funding total to $16.5m.
UTokyo enlivens EdiGene’s $15m series B
UTokyo's Innovation Platform joined subsidiaries of SBI, Sumitomo Mitsui and Mizuho Bank to help double genetic disorder treatment developer EdiGene's funding.
Fusion gets reaction in $105m series B
Varian led a round for the targeted cancer drug developer that included existing investors such as Facit and Johnson & Johnson.
SambaNova snags $150m
Stanford-founded AI application platform developer SambaNova has raised $150m in a series B round led by Intel Capital that also featured existing investor GV.
GeoSpock locates additional capital
Parkwalk Advisors has injected an additional $2.6m into GeoSpock, two months after the Cambridge spinout secured $12.8m in a round co-led by the fund manager.

Other News

Inivata invites investors to series B
IP Group, CIC and Johnson & Johnson have returned for a $52.2m series B round in Inivata, a spinout of Cancer Research UK and University of Cambridge.
Surrozen generates $50m series B
Based on Stanford research, Surrozen is working on regenerative treatments for a wide range of conditions, with a first focus on liver disease.
Mojo Vision sets $58m series B scene
Stanford-StartX has contributed to a $58m series B for AR platform Mojo Vision, which also attracted Google, HP, Motorola Solutions, LG and Kakao.
Garwood to spark $3m series B
Garwood Medical Devices is developing two therapeutic electrode-powered products based on licences from University of Buffalo, having last raised $3.6m in 2016.
Beam hits series B with $135m
GV participated as a new investor, as Harvard's genetic medicine developer Beam Therapeutics completed a round that followed $87m in series A funding last year.
Axial Biotherapeutics takes in $25m series B
Heritage Medical Systems has backed a $25m series B round for the Caltech spinout, which is developing therapies for Parkinson’s and Autism spectrum disorder.

Editor's Picks

Big deal: Ribon ties together $65m series B
Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.
Canvas paints $9m picture
Canvas Network, an online education platform developed by learning management software (LMS) provider Instructure which received $9.1m investment for the platform, has begun offering free and open online courses.
WRF finds its Resolve
In May 2010, Resolve raised $2m in the initial close of its A round before bringing in a corporate venturing unit later.
Imperial helps PsiOxus raise $34m
UK-listed investment fund Imperial Innovations joins GlaxoSmithKline's SR One, fund manager Invesco Perpetual and Lundbeckfond Ventures, backing the d cancer treatment company.
test reg

Login